

IFW

Please Direct All Correspondence to Customer Number **20995**

**TRANSMITTAL LETTER
INFORMATION DISCLOSURE STATEMENT**


Applicant : Landes et al.
App. No : 10/726,332
Filed : December 2, 2003
For : ANTIBODIES DIRECTED TO
PHOSPHOLIPASE A2 AND USES
THEREOF
Examiner : Francois P. Vandervegt
Art Unit : 1644

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

April 17, 2006

(Date)



Sheila R. Gibson, Reg. No. 54,120


Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
- (X) Listing 2 references.
 - (X) Enclosing 2 references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.



Sheila R. Gibson
Registration No. 54,120
Attorney of Record
Customer No. 20,995
(619) 235-8550

INFORMATION DISCLOSURE STATEMENT




Applicant : Landes et al.
App. No : 10/726,332
Filed : December 2, 2003
For : ANTIBODIES DIRECTED TO
PHOSPHOLIPASE A2 AND USES
THEREOF
Examiner : Francois P. Vandervegt
Art Unit : 1644

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box, 1450, Alexandria, VA 22313-1450, on

April 17, 2006

(Date)


Sheila R. Gibson, Reg. No. 54,120

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 2 references to be considered by the Examiner. Also enclosed are 2 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing date of a Notice of Allowance.

CERTIFICATION UNDER 37 C.F.R. § 1.97(e)(1)

I hereby certify that each item of information contained in this Statement was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

Thus, no fee is required as set forth in 37 C.F.R. § 1.97(c).

Appl. No. : 10/726,332
Filed : December 2, 2003

Docket No. ABGENIX.072A
Customer No. 20,995

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: April 17, 2006

By Sheila R. Gibson

Sheila R. Gibson

Registration No. 54,120

Attorney of Record

Customer No. 20,995

(619) 235-8550

2526952
041706

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

Application No. 10/726,332

Filing Date December 2, 2003

First Named Inventor Gregory M. Landes

Art Unit 1644

Examiner Francois P. Vandervegt

Attorney Docket No. ABGENIX.072A

(Multiple sheets used when necessary)

SHEET 1 OF 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	1	Schneider et al. "Lysine residues in bee venom phospholipase A2 are important for binding to human monoclonal or polyclonal antibodies of the IgG4 isotope. <i>Int. Arch. Allergy Immunol.</i> 104(3):262-269 (1994)	
	2	Schneider et al. "Human monoclonal or polyclonal antibodies recognize predominantly discontinuous epitopes on bee venom phospholipase A2. <i>J. Allergy Clin. Immunol.</i> 94(1):61-70 (1994).	

2526981
041706

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.